Safety of iliac vein stenting in the office-based laboratory: Experience with 4312 nonthrombotic iliac vein lesions Authors: Sundeep Srivastava, Enrico Ascher, Anil Hingorani Published: 2026 ABSTRACT ObjectiveThe study aims to evaluate the incidence of 30-day thrombosis after iliac vein stent placement, stratified by age, and to analyze long-term follow-up outcomes.MethodsA retrospective analysis was conducted of 4312 procedures performed in 2642 patients with symptomatic chronic venous insufficiency (Clinical, Etiologic, Anatomic, and Pathophysiologic [CEAP] clinical classes C3-C6) from 2012 to 2024. Patients underwent iliac vein assessment using intravascular ultrasound (IVUS) examination and received stent placement. Follow-up included iliac vein duplex ultrasound assessments at 3 to 7 days postoperatively, with additional evaluations at 3 to 6 months during the first year. For subsequent years, follow-up occurred at 6- to 12-month intervals. Intraoperative heparin was not administered, and postoperative management included daily clopidogrel (Plavix). Stents were assessed for partial and complete thrombosis.ResultsThe mean age of the study population was 73 years (range, 30-108 years), with 39.30% male and 60.70% female patients. Age distribution by decade, based on the number of nonthrombotic iliac vein lesions treated, was as follows: patients in their 30s (43), 40s (151), 50s (498), 60s (926), 70s (1116), 80s (1035), and >90s (543). Thirty-day thrombosis rates by age group were as follows: 30s (0%), 40s (0.01324%), 50s (0.0200%), 60s (0.0118%), 70s (0.0179%), 80s (0.0116%), and >90s (0.0074%). Thirty-day thrombosis rates by CEAP clinical class were as follows: C3 (0.01395%), C4 (0.0121%), C5 (0.0172%), and C6 (0.0166%). Among patients with thrombosis within 30 days of stent placement, 76.3% experienced partial stent thrombosis and 27.7% experienced complete stent thrombosis. The mean age of patients with complete thrombosis was 71.4 ± 17 years, compared with 71.8 ± 12 years for those with partial thrombosis. Of patients with complete thrombosis, 71.43% were female. Of the 14 patients with complete thrombosis within 30 days, 10 cases occurred between 2012 and 2021, three in 2022, and one in 2023. Binary logistic regression revealed no significant association between 30-day thrombosis and age (P = .719), CEAP clinical class (P = .938), or laterality (P = .326).ConclusionsIliac vein stenting for symptomatic nonthrombotic iliac vein lesions is a safe and effective procedure with a low incidence of early thrombosis. Age, laterality, and CEAP clinical class were not significantly associated with 30-day thrombosis outcomes. This study supports the use of iliac vein stenting in patients across a broad spectrum of chronic venous insufficiency severity, demonstrating its effectiveness in an office-based laboratory setting. Article Highlights •Type of Research: Single-center, retrospective cohort study•Key Findings: Among 4312 iliac vein stenting procedures for nonthrombotic iliac vein lesions, 30-day complete stent thrombosis occurred in 14 cases (0.32%) and was not significantly associated with age, laterality, or Clinical, Etiologic, Anatomic, and Pathophysiologic (CEAP) clinical classification.•Take Home Message: Early complete stent thrombosis after iliac vein stenting for nonthrombotic iliac vein lesions was uncommon across age groups and CEAP clinical classes. Article Highlights •Type of Research: Single-center, retrospective cohort study•Key Findings: Among 4312 iliac vein stenting procedures for nonthrombotic iliac vein lesions, 30-day complete stent thrombosis occurred in 14 cases (0.32%) and was not significantly associated with age, laterality, or Clinical, Etiologic, Anatomic, and Pathophysiologic (CEAP) clinical classification.•Take Home Message: Early complete stent thrombosis after iliac vein stenting for nonthrombotic iliac vein lesions was uncommon across age groups and CEAP clinical classes. •Type of Research: Single-center, retrospective cohort study Type of Research: Single-center, retrospective cohort study •Key Findings: Among 4312 iliac vein stenting procedures for nonthrombotic iliac vein lesions, 30-day complete stent thrombosis occurred in 14 cases (0.32%) and was not significantly associated with age, laterality, or Clinical, Etiologic, Anatomic, and Pathophysiologic (CEAP) clinical classification. Key Findings: Among 4312 iliac vein stenting procedures for nonthrombotic iliac vein lesions, 30-day complete stent thrombosis occurred in 14 cases (0.32%) and was not significantly associated with age, laterality, or Clinical, Etiologic, Anatomic, and Pathophysiologic (CEAP) clinical classification. •Take Home Message: Early complete stent thrombosis after iliac vein stenting for nonthrombotic iliac vein lesions was uncommon across age groups and CEAP clinical classes. Take Home Message: Early complete stent thrombosis after iliac vein stenting for nonthrombotic iliac vein lesions was uncommon across age groups and CEAP clinical classes. Nonthrombotic iliac vein lesions (NIVLs) are increasingly recognized as an important cause of chronic venous insufficiency (CVI). The widespread adoption of intravascular ultrasound (IVUS) examination has significantly enhanced the detection and diagnosis of these lesions, solidifying IVUS as the gold standard for evaluating iliac vein pathology.1 Iliac vein stenting (IVS) has become a preferred intervention for NIVL-associated CVI, offering high long-term patency rates, low morbidity, and the convenience of an outpatient procedure in office-based laboratories (OBLs).2,3 The benefits of IVS extend beyond technical success. For patients with significant iliac vein stenosis, IVS restores venous flow, alleviating chronic venous congestion and providing symptom relief, including reductions in leg discomfort, edema, and varicose veins, ultimately improving patients' quality of life.4, 5, 6 IVS is associated with a low rate of morbidity and a high rate of long-term patency, reinforcing its value as a durable therapeutic option.347 Major complications after IVS are rare in OBL settings, with minor issues typically resolving with minimal intervention.28 Studies have demonstrated the substantial clinical benefits of IVS, including superior symptom relief and functional improvements compared with medical management alone. Specifically, IVS has been associated with significant improvements in validated clinical measures, including reductions in visual analog scale pain score at 6 months (P < .001), Venous Clinical Severity Score (P < .001), and 36-Item Short Form Health Survey scores (P < .001).5 Despite these promising outcomes, stent thrombosis remains a significant concern postprocedure. This study evaluates the incidence of both partial and complete thrombosis after IVS in a large cohort of patients, with long-term follow-up. By analyzing factors such as age, laterality, and Clinical, Etiologic, Anatomic, and Pathophysiologic (CEAP) classification, we aim to refine risk stratification for thrombus formation. This represents one of the largest reported databases assessing thrombosis outcomes after IVS. Leveraging a robust dataset, our findings will help optimize patient selection and postprocedural management, ultimately improving outcomes for patients with NIVL undergoing IVS. Methods We conducted a retrospective analysis of 4312 NIVL procedures performed in 2642 patients with symptomatic CVI between 2012 and 2024. The study consisted of a retrospective, blinded review of existing data and was determined to pose minimal risk to patients. The Institutional Review Board of Total Vascular Care approved the study and granted a waiver of informed consent.9 All data collection and analyses were conducted in accordance with the principles outlined in the Declaration of Helsinki.9 Inclusion criteria required patients to have a CEAP clinical classification of C3 or higher. All patients had NIVLs, and all interventions were performed in OBL settings. The initial step in treatment was conservative therapy, including compression stockings, leg elevation, and lifestyle modifications, for a duration of at least 3 months. Only patients who failed conservative therapy were considered for further intervention with IVS. Lesion severity was assessed using IVUS, the gold standard for evaluating iliac vein pathology. IVUS was used in all patients beginning in 2012, which marked the start of uniform IVUS-guided evaluation across the cohort. Two IVUS systems were used throughout the study period, including the Philips IVUS system and the Boston Scientific IVUS system. Stent placement was performed only for patients whose lesions demonstrated greater than 50% luminal narrowing, measured by diameter or cross-sectional area, as determined by IVUS. Wallstents (Boston Scientific) were used for stent placement. In addition, we used two IVUS systems: the Philips system and the Boston Scientific system. Patients were stratified according to clinical presentation based on CEAP classification: C3 (edema), C4 (skin changes), C5 (healed ulcer), and C6 (active ulcer). Analyses were performed to assess the association of these clinical presentations with 30-day and long-term stent thrombosis. Stent thromboses were classified as either complete or partial. Complete thrombosis was defined as an entirely occluded vessel, whereas partial thrombosis referred to thrombus formation that did not result in full occlusion. It is important to note that partial thrombosis did not progress to complete thrombosis in any of the cases observed. Intraoperative management included no heparin administration, and postprocedure management involved daily clopidogrel (Plavix). No temporal practice-based changes occurred during the study period that would be expected to affect the reported outcomes. Specifically, device selection, periprocedural medication strategy, and operator practice remained consistent over time, including IVUS-guided assessment, Wallstent placement, absence of intraoperative heparin use, and postprocedural antiplatelet therapy with Plavix. Follow-up imaging included iliac vein duplex ultrasound evaluations at 3 to 7 days postoperatively, every 3 to 6 months during the first year, and at 6- to 12-month intervals thereafter. All patients in our cohort were managed according to this protocol, and only a very small number of cases (<1%) did not return for scheduled imaging, reflecting a high degree of follow-up completeness. The primary end point was the incidence of 30-day thrombosis, stratified by age, clinical presentation based on CEAP, partial vs complete thrombosis, and laterality. Follow-up duration was calculated from the date of stent placement to the date of the last documented duplex ultrasound examination of the iliac vein, with a range of 0 to 169.44 months (mean, 57.2 ± 112 months; median, 33.1 months). In this study, we focused specifically on technical and thrombotic outcomes after IVS. Clinical improvement was not systematically evaluated in this dataset, as the primary objective was to assess thrombotic-related end points. Clinical outcomes are evaluated in separate datasets within our research program. We considered performing multivariable logistic regression; however, given the low number of outcome events in our cohort, concerns were raised regarding model stability. A commonly cited guideline recommends approximately 10 outcome events per predictor variable to avoid unreliable estimates. With only 14 complete thrombosis events and three candidate predictors (age, laterality, and clinical presentation), a multivariable model was deemed likely to produce unstable estimates. Therefore, univariable logistic regression was used for all analyses. Regarding subgroup analyses and the reporting of P values for categorical variables (eg, age categories and CEAP classification), the very low number of thrombotic events within individual subgroups made calculation of subgroup-specific P values statistically unreliable and highly susceptible to type II error. In addition, multiple subgroup comparisons would have introduced an increased risk of spurious inference in the setting of limited event rates and inadequate statistical power. Therefore, individual subgroup P values were not calculated or reported. Instead, binary logistic regression was used as the primary inferential method to evaluate associations between baseline variables and 30-day thrombosis. Binary logistic regression analysis was performed using Minitab Statistical Software (version 21.4) to evaluate associations between 30-day thrombosis and age, laterality, clinical presentation, and thrombosis type. P values were calculated using Python, with significance defined as P < .05. Results A total of 4312 IVS procedures were performed for NIVLs. Among 2642 patients, the mean age was 73 years, and 60.7% were female. All patients in the cohort were managed according to the study protocol, which included scheduled duplex ultrasound examination and clinical surveillance. Follow-up data were available for the vast majority of treated NVILs. Fewer than 1% of patients did not return for scheduled imaging. Of the 4312 NVILs included in the study, 39 cases (0.9%) lacked documented follow-up. Overall, thrombotic complications were uncommon. During follow-up, 138 thrombotic events were identified, corresponding to an overall incidence of 3.2% per treated NIVL. Most thrombotic events were partial and unilateral (66%), followed by unilateral complete thrombosis (21.7%). Bilateral thrombotic events occurred in 17 cases (12.3%), including 15 cases of partial bilateral thrombosis (10.9%), one case of mixed unilateral thrombosis (complete on the right and partial on the left) (0.7%), and one case of complete bilateral thrombosis (0.7%). The number of partial stent thrombosis events is detailed in the Table. In total, there were 122 partial thrombotic NIVLs, including 91 unilateral partial NIVLs, 15 bilateral partial NIVLs, and one patient with mixed thrombosis (complete on the right side and partial on the left side). For comparison, complete stent thrombosis included 30 unilateral NIVLs, one bilateral NIVL, and the single patient with mixed complete/partial thrombosis.TableDistribution of thrombotic events after iliac vein stenting (N = 138)Thrombosis typeLateralityNo. of eventsPartialUnilateral91CompleteUnilateral30PartialBilateral15Complete (right) + partial (left)Mixed1CompleteBilateral1Values represent the number of thrombotic events among treated nonthrombotic iliac vein lesions. TableDistribution of thrombotic events after iliac vein stenting (N = 138)Thrombosis typeLateralityNo. of eventsPartialUnilateral91CompleteUnilateral30PartialBilateral15Complete (right) + partial (left)Mixed1CompleteBilateral1Values represent the number of thrombotic events among treated nonthrombotic iliac vein lesions. Distribution of thrombotic events after iliac vein stenting (N = 138) Values represent the number of thrombotic events among treated nonthrombotic iliac vein lesions. Complete stent thrombosis within 30 days occurred in 14 treated NIVLs (0.32%). Partial thrombosis accounted for 76.3% of all 30-day thrombotic events, representing early subclinical thrombus formation. These partial thromboses were primarily unilateral and did not progress to complete stent occlusion during follow-up, as reported in prior studies.10 When stratified by sex, 30-day complete stent thrombosis occurred in four male patients and 10 female patients. Among the total cohort, 1038 male (39.3%) and 1604 female patients (60.7%) underwent IVS. Statistical analysis revealed no significant association between sex and 30-day complete stent thrombosis (P = .971 for male patients, P = .089 for female patients), indicating that early thrombosis rates were similar across both sexes. When analyzed by year, the incidence of complete stent thrombosis within 30 days remained low and showed no consistent temporal trend. One event occurred in 2012 (1 of 219 NIVLs; P = .560), one in 2013 (1 of 705 NIVLs; P = .945), three in 2014 (3 of 771 NIVLs; P = .572), one in 2015 (1 of 615 NIVLs; P = .919), one in 2016 (1 of 492 NIVLs; P = .865), one in 2017 (1 of 300 NIVLs; P = .692), and none in 2018 (0 of 297 NIVLs) or 2019 (0 of 252 NIVLs), followed by one event in 2020 (1 of 242 NIVLs; P = .600), one in 2021 (1 of 224 NIVLs; P = .577), three in 2022 (3 of 141 NIVLs; P = .014), and one in 2023 (1 of 54 NIVLs; P = .177). For nearly all years, χ2 testing indicated no statistically significant difference in thrombosis incidence compared with other years (P > .05), with the exception of 2022, which showed a slightly higher event rate. Overall, these data suggest that early complete stent thrombosis occurred sporadically across the study period without a clear temporal pattern. When evaluating laterality, the majority of IVS procedures were performed bilaterally, with 3360 NIVLs treated on both sides, compared with 423 right-sided and 529 left-sided procedures. Among the 30-day complete stent thrombosis events, five occurred in right-sided NIVLs, eight in left-sided NIVLs, and one in a bilateral NIVL. Statistical analysis revealed no significant association between laterality and early thrombosis (P = .326), indicating that the risk of complete stent thrombosis within 30 days was similar regardless of whether the stent was placed on the right, left, or both sides. When analyzed by age group, the timing of complete stent thrombosis varied modestly across the cohort. No events were observed in patients in their 40s or 50s. Among patients in their 60s, one thrombosis occurred after more than 1 year of follow-up. In patients in their 70s, one event occurred between 60 and 90 days, four events at 1 year, and five events after more than 1 year. Among patients in their 80s, one event occurred between 60 and 90 days and three events after more than 1 year. For patients older than 90, one event occurred between 60 and 90 days, one at 6 months, and two after more than 1 year. These findings indicate that complete stent thrombosis was infrequent and occurred across a broad range of follow-up intervals, with a tendency for later events in older patients. When stratified by age decade, the overall incidence of complete stent thrombosis within 30 days was low across all groups. No events occurred in patients in their 30s. One event was observed in patients in their 40s (0.66% of 151 NIVLs), five events in the 50s (1.0% of 498 NIVLs), one event in the 60s (0.11% of 926 NIVLs), three events in the 70s (0.27% of 1116 NIVLs), one event in the 80s (0.10% of 1035 NIVLs), and three events in patients older than 90 (0.55% of 543 NIVLs). Overall, 14 events occurred among the 4312 NIVLs, highlighting the rarity of early complete stent thrombosis and showing that age decade did not strongly influence 30-day thrombosis risk. When analyzed by CEAP clinical classification, 30-day complete stent thrombosis occurred in four patients with CEAP C3 (of 1789 NIVLs), three patients with CEAP C4 (1672 NIVLs), two patients with CEAP C5 (363 NIVLs), and five patients with CEAP C6 (488 NIVLs). This corresponds to 30-day thrombosis rates of 0.014% for CEAP C3, 0.012% for CEAP C4, 0.017% for CEAP C5, and 0.017% for CEAP C6. Statistical testing using χ2 analysis indicated no significant difference in early thrombosis among the CEAP C3, C4, and C5 groups (P = .9565, .9792, and .3757, respectively), whereas the CEAP C6 group showed a slightly higher event rate (P = .0249). However, when considered across all categories, CEAP clinical classification was not significantly associated with 30-day thrombosis (overall P = .938). Binary logistic regression similarly revealed no significant association between thrombosis and clinical presentation or thrombosis type, indicating that early complete stent thrombosis risk remains generally low regardless of CEAP severity. Discussion This large, single-center OBL study of 4312 IVS procedures in 2642 patients demonstrates that early thrombosis after IVS for NIVLs is rare, even among elderly patients and those with advanced CEAP clinical presentation. These findings suggest that IVUS-guided stenting with single-agent antiplatelet therapy and no intraoperative heparin can be performed safely in an OBL setting. These findings suggest that endovenous stenting can be performed safely in such patients under local anesthesia with minimal sedation, without the need for routine hospital admission. Furthermore, standard Wallstents appear to provide acceptable outcomes in this setting, without the necessity for dedicated venous-specific stent platforms, which are associated with substantially higher cost. Partial iliac vein thrombosis was the most common early thrombotic event, accounting for 76.3% of 30-day thrombotic events. All partial thromboses were subclinical and did not progress to complete stent occlusion during follow-up. This highlights that IVS is associated with low rates of clinically significant thrombosis, supporting the safety and effectiveness of the procedure.10 In our cohort, routine reintervention was not performed for partial stent thrombosis, as these findings were generally asymptomatic and did not demonstrate progression to complete thrombosis. Intervention was reserved for cases with hemodynamically significant in-stent narrowing, typically 60% or greater, accompanied by symptoms rather than for imaging findings alone. This approach is supported by prior work from our group, which demonstrated that early partial in-stent thrombosis, particularly when involving less than 60% luminal compromise, is frequently clinically silent, does not progress to occlusion, and is not associated with pulmonary embolism or other adverse outcomes.10 Accordingly, the absence of routine reintervention in our current study reflects an evidence-based, conservative management approach in which treatment decisions are guided by symptomatology and degree of luminal compromise rather than the presence of partial thrombus alone. When intervention was required for thrombosed stents, patients were treated with percutaneous thrombectomy at our institution. In cases of significant thrombus burden, management followed our previously described fast-track thrombolysis protocol, which includes pharmacomechanical thrombectomy, adjunctive catheter-directed tissue plasminogen activator, balloon maceration of thrombus, and selective re-stenting when indicated. This approach is consistent with prior reports of single-session thrombolysis for acute iliofemoral deep venous thrombosis, in which 38 patients were treated using the fast-track thrombolysis protocol and 30 (79%) required IVS.11 Early thrombosis did not vary based on clinical presentation as defined by CEAP classification. Patients with edema (C3), skin changes (C4), healed ulcers (C5), or active ulcers (C6) experienced similarly low rates of 30-day thrombosis, indicating that IVS can be safely applied across the full spectrum of clinical presentation severity. In our data for CEAP clinical presentation, 30-day thrombosis rates for each group were low and nonsignificant (P = .938), supporting the finding that CEAP classification does not significantly affect early thrombotic risk. Our outcomes compare favorably with prior studies. Satwah et al2 reported early thrombosis in approximately 2% of cases in a multicenter cohort, whereas Raju4 observed a long-term patency of 90% to 100% in a younger, hospital-based population. Marston et al12 reported early patency losses despite routine low-molecular-weight heparin prophylaxis. Notably, our cohort was older (mean 73.5 years vs median 52 years in Raju's study) and managed entirely in an OBL setting, suggesting that IVS can be safely extended to populations traditionally considered at higher risk for thrombotic and bleeding complications.4 Differences in follow-up protocols likely influenced these outcomes. Raju4 conducted clinical evaluations at 6 weeks and then every 4 to 6 months, whereas our study used structured duplex follow-up. This more intensive early imaging schedule may have facilitated timely identification and management of thrombotic events, contributing to the low observed rates of early thrombosis and supporting safe care in an OBL, particularly in older patients. Consistent with prior literature,12,13 age, CEAP clinical presentation, and laterality were not significant predictors of early thrombosis. Despite advanced age and high CEAP class, early thrombotic events were rare. CEAP clinical presentation does not appear to materially affect early thrombotic risk in IVS performed in an OBL setting, although it remains relevant for long-term outcomes such as ulcer healing and recurrence.31415 Although age, laterality, and CEAP classification were not associated with 30-day thrombosis in our cohort, this finding is consistent with prior literature, suggesting that early thrombosis after IVS is relatively infrequent and not strongly driven by baseline demographic or clinical severity variables.12,13 In particular, prior work from our group evaluating a large cohort of iliac vein stents (1216 limbs in 844 patients) demonstrated similarly low rates of early thrombosis (approximately 1%).13 Furthermore, additional analyses from our institution have shown that technical factors such as stent diameter and length do not significantly influence early thrombotic outcomes, suggesting that early thrombosis may instead be related to patient-specific thrombogenic factors or periprocedural variables not fully captured in standard datasets.13,16 Importantly, mechanistic analyses of iliocaval stent thrombosis from our institution have demonstrated that thrombotic events (0.8%) are more commonly associated with lesion- and flow-related factors, particularly inadequate inflow, outflow obstruction, especially involving the common femoral vein, and the extent and chronicity of venous occlusion, rather than baseline demographics or stent characteristics such as diameter or length.17 These anatomic and hemodynamic variables are especially relevant in patients with thrombotic disease, in whom clot burden, occlusion length, and impaired inflow and outflow dynamics play a dominant role in thrombosis risk. Taken together, the low event rate observed in our study likely reflects the overall safety of IVS, particularly in a predominantly NIVL population. In this context, the absence of statistically significant predictors should be interpreted as a negative finding primarily applicable to patients with NIVL specifically, in whom baseline demographic and CEAP-related variables are less influential than local venous flow dynamics. In thrombotic patients, however, additional factors such as extent of prior thrombosis, occlusion length, and adequacy of venous inflow and outflow are major determinants of outcomes that are not fully represented in our cohort.17 Accordingly, although this represents a negative study in an NIVL population, it likely reflects both the low event rate and the limitations of conventional variables in capturing the underlying drivers of thrombosis in patients with NIVL specifically, where lesion characteristics and venous flow dynamics are the predominant determinants of early stent thrombosis. In a prior study conducted by our group evaluating the etiology of iliocaval stent thrombosis, IVUS and venography were reviewed in 18 patients presenting with complete stent thrombosis.17 We would like to emphasize that once a stent becomes thrombosed, the underlying lesion cannot be assessed on initial imaging because the lumen is completely obscured by thrombus, precluding meaningful evaluation of lesion morphology. Accordingly, all patients underwent suction thrombectomy followed by repeat venography and IVUS, which allowed accurate identification of underlying pathology. After thrombus removal, in-stent restenosis was identified in 11 of 18 patients (61%), common femoral vein inflow lesions in six of 18 patients (33%), and external iliac vein lesions distal to the stent in two of 18 patients (11%), with no proximal lesions above the stented segment identified.17 These findings suggest that in-stent restenosis and inadequate inflow or outflow are the principal contributors to stent thrombosis in this cohort. All stents in this series were Wallstents, and most cases involved common iliac vein compression consistent with May-Thurner-type anatomy, although additional distal venous disease was frequently present. Importantly, residual or previously unrecognized inflow and outflow lesions were often only identified after thrombectomy, highlighting the limitations of diagnostic imaging in the setting of acute occlusion. However, this study did not evaluate potential contributors such as stent positioning relative to pelvic curvature, geometric alignment at the iliocaval confluence, or intrinsic structural characteristics of the Wallstent; therefore, these factors could not be assessed as mechanistic contributors within that dataset.17 Overall, these findings underscore the importance of thorough post-thrombectomy imaging with IVUS to identify correctable lesions, as well as meticulous attention to inflow and outflow optimization at the time of initial stent placement. The temporal pattern of stent thrombosis was not the primary focus of the present study and was not designed as a time-to-event analysis. Accordingly, interpretation of the temporal distribution of thrombosis events is limited and should be considered exploratory. These findings should therefore be interpreted as preliminary, and longer-term follow-up is ongoing. The use of Kaplan-Meier survival analysis with log-rank testing was considered to evaluate thrombosis-free survival over time. However, the very low event rate resulted in nearly flat survival curves, limiting the interpretability and additional clinical insight of such an approach. Specifically, complete stent thrombosis within 30 days occurred in only 14 treated NIVLs (0.32%), and 19 total complete thrombosis events were observed at ≥60 days. Partial thrombosis events were clinically insignificant, as they were asymptomatic, did not require intervention, demonstrated no progression to complete thrombosis, and were not associated with pulmonary embolism or other adverse outcomes. Given their limited clinical impact, time-to-event modeling of partial thrombosis was not performed, as it would not have meaningfully contributed to outcome interpretation. Accordingly, the presentation of temporal outcomes in this study focuses on clinically significant complete stent thrombosis, while partial thrombosis is reported descriptively to provide procedural context without overstating its clinical relevance. These findings suggest that early stent thrombosis is a multifactorial and predominantly technical or physiologic phenomenon, rather than one predicted by standard clinical variables.17 Accordingly, the absence of statistically significant predictors in our study likely reflects both the low event rate and the limitations of conventional variables in capturing the underlying drivers of thrombosis. Despite the low rates of early thrombosis observed in our cohort, the clinical benefit of IVS extends beyond technical success. Although systematic collection of patient-reported symptom outcomes was not performed in the current cohort, prior work from our group has demonstrated meaningful clinical improvement after IVS. In a comparative study of 726 patients who underwent both IVS and venous ablation, 83.3% of patients reported improvement in lower extremity swelling after completion of procedures, with a significant proportion indicating that IVS was the preferred intervention for symptom relief.18 These findings support the broader clinical effectiveness of IVS in improving venous symptoms and functional outcomes in appropriately selected patients, beyond its favorable technical and thrombotic performance. In addition to optimizing inflow and outflow, careful stent sizing and vessel preparation are critical procedural considerations. In our prior studies of iliac vein interventions, stent sizing was guided by IVUS measurements, with treatment typically performed for lesions demonstrating >50% area or diameter reduction.1,19 Stent diameters were selected to approximate the native vessel size, with commonly reported ranges of 12 to 24 mm depending on the target vessel (eg, common iliac vs external iliac vein).19 Stent lengths were chosen based on lesion extent to ensure complete coverage with adequate proximal and distal landing zones, with longer or overlapping stents used for more extensive disease.19 With respect to vessel preparation, our practice has evolved over time. Although predilation was performed in earlier studies, subsequent analyses from our group demonstrated no significant benefit of routine prestent dilation on clinical or patency outcomes. Similarly, prior work evaluating postdilation showed no added benefit in terms of stent patency in NIVL.19 Based on these findings, routine balloon angioplasty is no longer performed in our current practice.19 Instead, ballooning is reserved selectively for cases of clearly suboptimal stent expansion or malapposition on IVUS. Overall, this approach reflects an evidence-based evolution in technique, emphasizing IVUS-guided stent sizing and deployment while limiting adjunctive interventions to cases in which they are clearly indicated. In addition to defining the technical contributors to iliocaval stent thrombosis, Hingorani and collegues20 have reported midterm clinical outcomes after iliac vein stent placement. In a series of 268 stents placed for NIVLs, median follow-up exceeded 1 year, with a primary stent patency of 98.7% at 6 months and 98.3% at 1 year, and only four of 268 limbs (1.5%) experiencing in-stent thrombosis during the surveillance period.20 These results demonstrate that, when stents are deployed with meticulous IVUS guidance and optimized inflow and outflow segments, clinically significant thrombosis within the first year is uncommon and midterm durability is excellent. The timing of thrombosis events, therefore, appears to be closely related to procedural and technical factors rather than patient age or comorbid status. This reinforces the importance of careful stent placement and systematic imaging surveillance to maintain patency over time. Although the current study demonstrates the safety and low thrombosis rates of IVS, it does not provide direct evidence of clinical efficacy or symptomatic improvement, which remain areas for future investigation. An additional limitation of this study is that we do not have complete data on the total number of patients with CEAP C3 or higher disease who were successfully managed with conservative therapy alone and did not proceed to IVS. The data analyzed in this article are derived from patients who underwent IVS within a single high-volume, multisite practice comprising more than 15 to 20 treatment locations distributed across four boroughs of New York City. Our practice has been established since 1989 and operates 7 days a week, providing highly accessible care across all sites, with approximately 15,000 to 20,000 patient visits annually encompassing both arterial and venous disease. Although we are unable to provide a complete conservative-treatment denominator, all patients included in this study had failed at least 3 months of conservative therapy before stent placement, in accordance with standard clinical practice. Accordingly, a true denominator for all patients evaluated within our practice who may have improved with conservative therapy alone cannot be established, and the study cohort therefore reflects outcomes in a selected treatment population rather than the full spectrum of patients presenting with CVI. The primary strength of this study is its large sample size, including 4312 IVS procedures in 2642 patients over a 12-year period, providing strong statistical power and relevance to OBL vascular practices. The involvement of four practitioners reduces single-operator bias. Consistent use of an IVUS-guided stent placement protocol and structured duplex ultrasound follow-up allowed standardized assessment of early thrombosis and stent patency. Stratification by age, CEAP clinical presentation, and laterality adds further granularity, showing that low early thrombosis rates were maintained across clinical and anatomical subgroups. Several limitations should be acknowledged. The retrospective, single-center design introduces potential selection bias and may limit generalizability to centers with different patient populations, procedural practices, or postoperative protocols. Some variables that could influence thrombosis risk, including adherence to antiplatelet therapy, hypercoagulable conditions, major comorbidities such as malignancy or prior DVT, and lesion length, were not consistently documented. The study also lacked a comparator group, such as patients treated with alternative anticoagulation strategies, limiting evaluation of relative effectiveness. Long-term follow-up imaging was not always uniform, which may underestimate very late thrombotic events.21 These factors highlight the need for prospective, multicenter studies to confirm these findings and refine individualized anticoagulation and surveillance strategies. Despite these limitations, the large cohort size, consistent IVUS-guided protocol, and structured follow-up provide meaningful insight into early thrombosis risk after outpatient IVS for NIVL. Although this study demonstrates low rates of early thrombosis, it was not designed to provide a comprehensive assessment of safety outcomes. DVT involving the iliac venous system is associated with both early and late clinically significant complications. Acutely, there is a risk of pulmonary embolism, while over the longer term, patients are at risk for developing post-thrombotic syndrome. This continuum of risk underscores that safety remains a central consideration in the evaluation and application of these procedures. Importantly, safety is a key consideration for clinicians and investigators in this field, particularly those developing new studies and clinical programs. Accordingly, further prospective studies are needed to better define the full safety profile of IVS. Conclusions IVS for NIVLs is a safe and effective intervention with a very low incidence of early (30-day) stent thrombosis. Age, CEAP, and laterality do not significantly impact the risk of early thrombosis. These findings support the use of IVS across a broad patient population, including elderly patients, and highlight the importance of procedural technique and postoperative management in optimizing outcomes. Author Contributions Conception and design: SS, EA, AH Analysis and interpretation: SS, EA, AH Data collection: SS Writing the article: SS Critical revision of the article: SS, EA, AH Final approval of the article: SS, EA, AH Statistical analysis: SS, AH Obtained funding: Not applicable Overall responsibility: SS Funding None. Disclosures None.